A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Key facts

Sponsor

International AIDS Vaccine Initiative

Intervention

rVSV∆G-MARV-GP(biological)

Enrollment

112 enrolled

Eligibility

18-50 years · All sexes

Timeline

2026 – 2028

Study locations (3)

• George Washington University, Washington D.C., District of Columbia, United States
• Johnson County Clin-Trials, Lenexa, Kansas, United States
• CTI Clinical Research Center, Norwood, Ohio, United States

Collaborators

Biomedical Advanced Research and Development Authority

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Marburg hemorrhagic fever

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT06620003
  A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
  Albert B. Sabin Vaccine Institute

See all trials for Marburg hemorrhagic fever →